Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Courses
  4. ESMO Advanced Course on PARP Inhibition: Therapeutic Applications in Oncology 2024: Barcelona

Session 3 – Comparing efficacy of PARP inhibition across tumour types 

Rationale and development of PARPi adjuvant versus advanced or relapse: Ovary and breast examples 

Date

29 Oct 2024

Session

Session 3 – Comparing efficacy of PARP inhibition across tumour types 

Topics

Targeted Therapy

Tumour Site

Breast Cancer;  Ovarian Cancer

Presenters

F. André, FR and I. Ray-Coquard, FR 

Resources

This content is available to ESMO members and event participants.
Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.